Sermorelin

Quick Summary

Sermorelin is a synthetic version of the first 29 amino acids of human GHRH, the shortest fragment that retains full biological signaling activity at the GHRH receptor. It has a longer clinical history than CJC-1295 and was previously marketed in the United States under the Geref name. That historical approval should not be described as a currently marketed FDA-approved anti-aging or weight-loss therapy.

Identity and Position in the Axis

Sermorelin is also described as GRF (1-29) or GHRH (1-29). It stimulates pituitary release of endogenous GH and sits upstream of GH and IGF-1. Unlike CJC-1295 with DAC, Sermorelin does not include an albumin-binding extension designed to produce multi-day exposure.

Approval History

Sermorelin acetate products were historically approved for diagnostic and pediatric growth-related uses. The branded products were later discontinued. Discontinuation history, approved indication and current compounded use are separate questions. A compounded Sermorelin preparation is not itself an FDA-approved product and should not inherit the old label automatically.

Human Evidence

Human research and historical clinical use establish that Sermorelin can stimulate GH secretion and can be used to evaluate pituitary reserve. The evidence base does not support treating every age-related decline in GH as a disease, and historical pediatric or diagnostic evidence cannot automatically establish adult anti-aging, bodybuilding or general weight-loss benefits.

Sermorelin vs CJC-1295

Both act through the GHRH receptor. Sermorelin uses the native active fragment and is rapidly cleared. CJC-1295 contains stabilizing substitutions and, in its DAC form, an albumin-binding group that extends exposure. CJC-1295 has human pharmacokinetic evidence for sustained GH and IGF-1 elevation; Sermorelin has a longer historical medical record. Neither difference determines an appropriate treatment for an individual.

Safety

Historical drug information describes injection-site reactions, flushing, headache, dizziness and hypersensitivity concerns. Safety conclusions depend on product quality, route, population and monitoring. Claims that stimulating “natural” GH is inherently safe are not an evidence standard.

Sports Status

WADA includes Sermorelin among prohibited GHRH analogues. Tested athletes need to consider the current prohibited list and formal therapeutic-use exemption rules rather than commercial clinic claims.

Evidence Gaps

• No currently marketed FDA-approved Sermorelin product in the United States.
• Limited evidence for broad anti-aging and body-composition marketing claims.
• Compounded products do not automatically share the approval status of discontinued branded products.

Primary References

• Drugs@FDA database.
• Mayo Clinic drug information for Sermorelin.
• WADA Prohibited List.